| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 29 | 2024 | 329 | 4.780 |
Why?
|
| Molecular Diagnostic Techniques | 20 | 2024 | 132 | 4.480 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 19 | 2024 | 226 | 3.420 |
Why?
|
| HIV Infections | 45 | 2023 | 5097 | 3.030 |
Why?
|
| Tuberculosis, Pulmonary | 17 | 2024 | 324 | 2.580 |
Why?
|
| Sensitivity and Specificity | 37 | 2024 | 385 | 2.270 |
Why?
|
| Tuberculosis | 13 | 2023 | 543 | 2.220 |
Why?
|
| HIV-1 | 18 | 2020 | 1260 | 2.170 |
Why?
|
| Viral Load | 14 | 2020 | 819 | 2.010 |
Why?
|
| CD4 Lymphocyte Count | 16 | 2018 | 656 | 1.910 |
Why?
|
| Point-of-Care Testing | 8 | 2022 | 71 | 1.860 |
Why?
|
| Humans | 100 | 2024 | 14537 | 1.830 |
Why?
|
| Antibiotics, Antitubercular | 7 | 2021 | 47 | 1.500 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2022 | 59 | 1.500 |
Why?
|
| Rifampin | 15 | 2024 | 197 | 1.410 |
Why?
|
| Adult | 40 | 2024 | 5913 | 1.160 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2024 | 198 | 1.160 |
Why?
|
| Reagent Kits, Diagnostic | 6 | 2021 | 56 | 1.120 |
Why?
|
| Algorithms | 4 | 2020 | 106 | 1.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2018 | 195 | 1.040 |
Why?
|
| South Africa | 48 | 2024 | 7596 | 1.030 |
Why?
|
| Sputum | 13 | 2023 | 135 | 1.020 |
Why?
|
| Point-of-Care Systems | 9 | 2020 | 91 | 1.020 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 56 | 0.980 |
Why?
|
| Coinfection | 3 | 2017 | 276 | 0.960 |
Why?
|
| Drug Resistance, Bacterial | 11 | 2024 | 135 | 0.940 |
Why?
|
| Middle Aged | 26 | 2022 | 3601 | 0.930 |
Why?
|
| RNA, Viral | 11 | 2022 | 303 | 0.920 |
Why?
|
| Young Adult | 22 | 2023 | 2498 | 0.910 |
Why?
|
| Male | 35 | 2024 | 6754 | 0.900 |
Why?
|
| Primary Health Care | 6 | 2020 | 240 | 0.870 |
Why?
|
| Biological Assay | 2 | 2020 | 32 | 0.870 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2022 | 101 | 0.830 |
Why?
|
| Female | 35 | 2024 | 9103 | 0.800 |
Why?
|
| Bacteriological Techniques | 5 | 2017 | 54 | 0.790 |
Why?
|
| Health Personnel | 3 | 2021 | 231 | 0.770 |
Why?
|
| Flow Cytometry | 5 | 2017 | 67 | 0.760 |
Why?
|
| Immunophenotyping | 3 | 2017 | 24 | 0.740 |
Why?
|
| Antitubercular Agents | 7 | 2024 | 322 | 0.730 |
Why?
|
| Caregivers | 1 | 2021 | 76 | 0.710 |
Why?
|
| Adolescent | 14 | 2020 | 2985 | 0.690 |
Why?
|
| Mass Screening | 7 | 2023 | 245 | 0.670 |
Why?
|
| Lamivudine | 1 | 2020 | 89 | 0.660 |
Why?
|
| Anti-HIV Agents | 9 | 2020 | 1324 | 0.650 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 85 | 0.650 |
Why?
|
| Drug Monitoring | 3 | 2019 | 55 | 0.640 |
Why?
|
| Patient Compliance | 2 | 2017 | 120 | 0.640 |
Why?
|
| Cost of Illness | 1 | 2020 | 167 | 0.630 |
Why?
|
| Aged | 11 | 2022 | 1740 | 0.630 |
Why?
|
| Deoxycytidine | 2 | 2012 | 12 | 0.620 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2017 | 151 | 0.610 |
Why?
|
| Nucleic Acid Amplification Techniques | 4 | 2022 | 35 | 0.600 |
Why?
|
| Isoniazid | 7 | 2024 | 110 | 0.600 |
Why?
|
| Directive Counseling | 1 | 2017 | 15 | 0.570 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 38 | 0.560 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 13 | 0.560 |
Why?
|
| Blood | 2 | 2015 | 51 | 0.550 |
Why?
|
| Dengue Vaccines | 1 | 2016 | 1 | 0.540 |
Why?
|
| Dengue | 1 | 2016 | 5 | 0.540 |
Why?
|
| Eczema | 1 | 2016 | 4 | 0.540 |
Why?
|
| Tretinoin | 1 | 2016 | 8 | 0.540 |
Why?
|
| Reproducibility of Results | 9 | 2020 | 217 | 0.500 |
Why?
|
| Oxazoles | 1 | 2015 | 4 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 256 | 0.480 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 24 | 0.470 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2014 | 6 | 0.460 |
Why?
|
| Medical Laboratory Personnel | 1 | 2013 | 1 | 0.450 |
Why?
|
| Drug Resistance, Viral | 5 | 2020 | 278 | 0.440 |
Why?
|
| Prospective Studies | 7 | 2021 | 1160 | 0.420 |
Why?
|
| Nitriles | 1 | 2012 | 27 | 0.410 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 11 | 0.410 |
Why?
|
| Pyrimidines | 1 | 2012 | 32 | 0.410 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2017 | 118 | 0.400 |
Why?
|
| Organophosphonates | 1 | 2012 | 45 | 0.400 |
Why?
|
| Adenine | 1 | 2012 | 91 | 0.390 |
Why?
|
| Child | 7 | 2024 | 2242 | 0.380 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 231 | 0.380 |
Why?
|
| HIV Protease Inhibitors | 2 | 2010 | 92 | 0.370 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 284 | 0.370 |
Why?
|
| Drug Combinations | 3 | 2020 | 42 | 0.360 |
Why?
|
| Pyrrolidinones | 1 | 2010 | 6 | 0.350 |
Why?
|
| Sulfonamides | 1 | 2010 | 10 | 0.350 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2010 | 33 | 0.340 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 468 | 0.340 |
Why?
|
| Immunoglobulin A | 2 | 2021 | 39 | 0.330 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2022 | 150 | 0.330 |
Why?
|
| Automation | 1 | 2009 | 8 | 0.330 |
Why?
|
| Virology | 1 | 2009 | 13 | 0.330 |
Why?
|
| Blood Specimen Collection | 2 | 2020 | 13 | 0.290 |
Why?
|
| Prevalence | 7 | 2021 | 1192 | 0.280 |
Why?
|
| DNA, Bacterial | 4 | 2021 | 53 | 0.280 |
Why?
|
| Treatment Outcome | 4 | 2013 | 889 | 0.280 |
Why?
|
| Specimen Handling | 4 | 2020 | 105 | 0.270 |
Why?
|
| Autoantigens | 2 | 2016 | 10 | 0.250 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 5 | 0.250 |
Why?
|
| Whole Genome Sequencing | 2 | 2024 | 44 | 0.250 |
Why?
|
| Membrane Proteins | 2 | 2016 | 36 | 0.250 |
Why?
|
| Child, Preschool | 6 | 2018 | 1748 | 0.250 |
Why?
|
| Pyridines | 1 | 2005 | 11 | 0.240 |
Why?
|
| Time Factors | 5 | 2014 | 507 | 0.240 |
Why?
|
| Oligopeptides | 1 | 2005 | 16 | 0.240 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 23 | 0.240 |
Why?
|
| Developing Countries | 6 | 2016 | 400 | 0.240 |
Why?
|
| Immunoassay | 2 | 2022 | 28 | 0.230 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 279 | 0.230 |
Why?
|
| Consent Forms | 1 | 2024 | 2 | 0.230 |
Why?
|
| Informed Consent | 1 | 2024 | 8 | 0.230 |
Why?
|
| Biometry | 1 | 2003 | 5 | 0.220 |
Why?
|
| Administration, Oral | 2 | 2016 | 127 | 0.220 |
Why?
|
| Reference Standards | 3 | 2019 | 29 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 260 | 0.210 |
Why?
|
| Models, Statistical | 1 | 2003 | 55 | 0.210 |
Why?
|
| Plasma | 2 | 2020 | 39 | 0.210 |
Why?
|
| Retrospective Studies | 3 | 2022 | 799 | 0.200 |
Why?
|
| Infant | 7 | 2018 | 2244 | 0.200 |
Why?
|
| Feasibility Studies | 4 | 2022 | 101 | 0.200 |
Why?
|
| Sequence Deletion | 1 | 2021 | 16 | 0.190 |
Why?
|
| Databases, Genetic | 1 | 2021 | 22 | 0.190 |
Why?
|
| Drug Interactions | 2 | 2016 | 31 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2022 | 31 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 8 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2020 | 967 | 0.190 |
Why?
|
| HIV | 5 | 2013 | 380 | 0.190 |
Why?
|
| Genome, Viral | 1 | 2021 | 64 | 0.190 |
Why?
|
| Students, Medical | 2 | 2013 | 14 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2008 | 187 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 127 | 0.190 |
Why?
|
| Delavirdine | 1 | 2000 | 1 | 0.180 |
Why?
|
| Health Plan Implementation | 2 | 2017 | 16 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2020 | 7 | 0.180 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.170 |
Why?
|
| HIV-2 | 1 | 2020 | 15 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.170 |
Why?
|
| Quality Control | 4 | 2014 | 27 | 0.170 |
Why?
|
| Asia | 2 | 2017 | 72 | 0.170 |
Why?
|
| Tablets | 1 | 2020 | 39 | 0.170 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 44 | 0.170 |
Why?
|
| Piperazines | 1 | 2020 | 82 | 0.160 |
Why?
|
| Oxazines | 1 | 2020 | 81 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2021 | 321 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 175 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2016 | 472 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 100 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 1422 | 0.160 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 57 | 0.160 |
Why?
|
| Rifabutin | 1 | 2018 | 4 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
| Pregnancy | 3 | 2024 | 1862 | 0.160 |
Why?
|
| Feces | 1 | 2018 | 30 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 239 | 0.150 |
Why?
|
| Arthritis, Reactive | 1 | 1998 | 2 | 0.150 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1998 | 6 | 0.150 |
Why?
|
| Emtricitabine | 2 | 2012 | 78 | 0.150 |
Why?
|
| Antigen-Antibody Complex | 1 | 1998 | 11 | 0.150 |
Why?
|
| Dentist-Patient Relations | 2 | 2015 | 2 | 0.150 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 563 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.150 |
Why?
|
| Time-to-Treatment | 2 | 2015 | 42 | 0.150 |
Why?
|
| Communication | 2 | 2015 | 57 | 0.140 |
Why?
|
| Analysis of Variance | 1 | 2017 | 64 | 0.140 |
Why?
|
| Chromatography, Affinity | 1 | 2017 | 8 | 0.140 |
Why?
|
| Dengue Virus | 1 | 2016 | 1 | 0.140 |
Why?
|
| Latin America | 1 | 2016 | 10 | 0.140 |
Why?
|
| Dermatologic Agents | 1 | 2016 | 6 | 0.140 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2018 | 5 | 0.130 |
Why?
|
| Vaccines, Attenuated | 1 | 2016 | 28 | 0.130 |
Why?
|
| Laboratories | 2 | 2015 | 47 | 0.130 |
Why?
|
| bcl-X Protein | 1 | 2016 | 1 | 0.130 |
Why?
|
| Infection Control | 1 | 2016 | 31 | 0.130 |
Why?
|
| Sex Workers | 1 | 2017 | 116 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1998 | 158 | 0.130 |
Why?
|
| HIV Antibodies | 2 | 2010 | 247 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2016 | 43 | 0.130 |
Why?
|
| Apoptosis | 1 | 2016 | 40 | 0.130 |
Why?
|
| Lymphoma | 1 | 2015 | 4 | 0.130 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 119 | 0.120 |
Why?
|
| Education, Dental | 1 | 2015 | 2 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 3 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 11 | 0.120 |
Why?
|
| Cues | 1 | 2014 | 3 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2014 | 5 | 0.120 |
Why?
|
| Emotions | 1 | 2014 | 18 | 0.120 |
Why?
|
| Body Fluids | 1 | 2014 | 5 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2014 | 57 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2014 | 13 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 34 | 0.110 |
Why?
|
| Mobile Health Units | 1 | 2014 | 7 | 0.110 |
Why?
|
| Community Health Services | 1 | 2014 | 58 | 0.110 |
Why?
|
| Mutation | 3 | 2022 | 306 | 0.110 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2013 | 8 | 0.110 |
Why?
|
| Prognosis | 3 | 2022 | 199 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2013 | 45 | 0.110 |
Why?
|
| Rilpivirine | 1 | 2012 | 7 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2013 | 54 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 106 | 0.100 |
Why?
|
| Phylogeny | 3 | 2022 | 231 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2014 | 1479 | 0.100 |
Why?
|
| HIV Seropositivity | 3 | 2013 | 265 | 0.100 |
Why?
|
| Glomerulonephritis | 1 | 2011 | 7 | 0.100 |
Why?
|
| Streptococcus pyogenes | 1 | 2011 | 5 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 25 | 0.100 |
Why?
|
| Antiviral Agents | 2 | 2009 | 111 | 0.090 |
Why?
|
| Tenofovir | 1 | 2012 | 171 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 551 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 37 | 0.090 |
Why?
|
| World Health Organization | 2 | 2022 | 137 | 0.090 |
Why?
|
| Darunavir | 1 | 2010 | 12 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 10 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2010 | 20 | 0.090 |
Why?
|
| Raltegravir Potassium | 1 | 2010 | 14 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2010 | 16 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 34 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 77 | 0.090 |
Why?
|
| Ethionamide | 2 | 2021 | 9 | 0.080 |
Why?
|
| Ritonavir | 1 | 2010 | 137 | 0.080 |
Why?
|
| Nasopharynx | 2 | 2022 | 151 | 0.080 |
Why?
|
| Oseltamivir | 1 | 2009 | 3 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 112 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 2011 | 184 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 188 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2009 | 54 | 0.080 |
Why?
|
| Urethritis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Ciprofloxacin | 1 | 2008 | 11 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 40 | 0.080 |
Why?
|
| Logistic Models | 2 | 2023 | 254 | 0.080 |
Why?
|
| Gonorrhea | 1 | 2008 | 20 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 54 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2008 | 3 | 0.070 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 57 | 0.070 |
Why?
|
| Comprehensive Health Care | 1 | 2008 | 5 | 0.070 |
Why?
|
| Research Design | 3 | 2019 | 124 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 40 | 0.070 |
Why?
|
| Belgium | 2 | 2018 | 6 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 370 | 0.070 |
Why?
|
| International Cooperation | 1 | 2008 | 50 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 43 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2015 | 14 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2006 | 325 | 0.070 |
Why?
|
| HIV Seroprevalence | 1 | 2006 | 15 | 0.070 |
Why?
|
| DNA Primers | 1 | 2006 | 55 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 5 | 0.060 |
Why?
|
| Mining | 1 | 2006 | 41 | 0.060 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 23 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 20 | 0.060 |
Why?
|
| Atazanavir Sulfate | 1 | 2005 | 10 | 0.060 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 8 | 0.060 |
Why?
|
| Creatinine | 2 | 2016 | 53 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2009 | 374 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 13 | 0.060 |
Why?
|
| CD4 Antigens | 2 | 2016 | 49 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2016 | 40 | 0.060 |
Why?
|
| Moldova | 1 | 2024 | 3 | 0.060 |
Why?
|
| India | 1 | 2024 | 62 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2005 | 79 | 0.060 |
Why?
|
| Statistical Distributions | 1 | 2003 | 2 | 0.050 |
Why?
|
| Cognition | 1 | 2024 | 75 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 125 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 37 | 0.050 |
Why?
|
| Refugees | 1 | 2002 | 10 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2002 | 3 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.050 |
Why?
|
| Botswana | 1 | 2022 | 24 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 27 | 0.050 |
Why?
|
| Capreomycin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Kanamycin | 1 | 2021 | 5 | 0.050 |
Why?
|
| Amikacin | 1 | 2021 | 7 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2022 | 84 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 48 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2021 | 20 | 0.050 |
Why?
|
| Mozambique | 1 | 2021 | 55 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 24 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 90 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2000 | 7 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2000 | 32 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2020 | 12 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 109 | 0.040 |
Why?
|
| Fluorometry | 1 | 1999 | 1 | 0.040 |
Why?
|
| Zambia | 1 | 2020 | 115 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1999 | 48 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 303 | 0.040 |
Why?
|
| Animals | 1 | 2022 | 1081 | 0.040 |
Why?
|
| Synovial Fluid | 1 | 1998 | 1 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 6 | 0.040 |
Why?
|
| Joints | 1 | 1998 | 9 | 0.040 |
Why?
|
| Biomarkers | 1 | 2019 | 327 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 99 | 0.040 |
Why?
|
| Brazil | 1 | 2017 | 47 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 56 | 0.040 |
Why?
|
| Viremia | 1 | 2017 | 66 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 293 | 0.030 |
Why?
|
| Facility Design and Construction | 1 | 2016 | 1 | 0.030 |
Why?
|
| Ventilation | 1 | 2016 | 1 | 0.030 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2016 | 1 | 0.030 |
Why?
|
| Masks | 1 | 2016 | 4 | 0.030 |
Why?
|
| Hand Disinfection | 1 | 2016 | 9 | 0.030 |
Why?
|
| Africa | 1 | 2017 | 376 | 0.030 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2016 | 11 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2016 | 3 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 20 | 0.030 |
Why?
|
| Operations Research | 1 | 2016 | 3 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 442 | 0.030 |
Why?
|
| United States | 1 | 2016 | 132 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 25 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 71 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2016 | 34 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2000 | 529 | 0.030 |
Why?
|
| Health Policy | 1 | 2017 | 140 | 0.030 |
Why?
|
| Dentistry | 1 | 2015 | 1 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2015 | 1 | 0.030 |
Why?
|
| E2F1 Transcription Factor | 1 | 2015 | 1 | 0.030 |
Why?
|
| Teaching | 1 | 2015 | 8 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 50 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 163 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 96 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2014 | 1 | 0.030 |
Why?
|
| Videotape Recording | 1 | 2014 | 2 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 49 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 154 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 15 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 5 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 262 | 0.030 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2013 | 8 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2014 | 89 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2013 | 49 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 133 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 17 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2012 | 16 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2013 | 39 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 17 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 115 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 63 | 0.020 |
Why?
|
| Northern Territory | 1 | 2011 | 1 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 105 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 280 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 253 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2011 | 111 | 0.020 |
Why?
|
| Acids, Carbocyclic | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cyclopentanes | 1 | 2009 | 1 | 0.020 |
Why?
|
| Oceania | 1 | 2009 | 2 | 0.020 |
Why?
|
| Zanamivir | 1 | 2009 | 3 | 0.020 |
Why?
|
| Neuraminidase | 1 | 2009 | 4 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2009 | 7 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2009 | 11 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 685 | 0.020 |
Why?
|
| Guanidines | 1 | 2009 | 8 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 35 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 65 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 1475 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2009 | 65 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 181 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2008 | 13 | 0.020 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2008 | 15 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2008 | 14 | 0.020 |
Why?
|
| Fluorescence | 1 | 2008 | 9 | 0.020 |
Why?
|
| Software | 1 | 2006 | 37 | 0.020 |
Why?
|
| Mass Chest X-Ray | 1 | 2002 | 1 | 0.010 |
Why?
|
| Indonesia | 1 | 2002 | 7 | 0.010 |
Why?
|
| Fixatives | 1 | 2001 | 1 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 2001 | 52 | 0.010 |
Why?
|
| Tanzania | 1 | 2001 | 88 | 0.010 |
Why?
|